BRCA Status, Molecular Markers, and Clinical Variables in Early, Conservatively Managed Breast Cancer
| Autor: | Sung Kim, Mayra Alvarez Franco, Atif J. Khan, Nicole Parisot, Allen E. Bale, David L. Rimm, Darryl Carter, Bruce G. Haffty |
|---|---|
| Rok vydání: | 2003 |
| Předmět: |
Adult
Oncology medicine.medical_specialty animal structures endocrine system diseases Receptor ErbB-2 medicine.medical_treatment Estrogen receptor Breast Neoplasms Cohort Studies Breast cancer Proliferating Cell Nuclear Antigen Internal medicine Biomarkers Tumor Internal Medicine medicine Genetic predisposition Humans Genetic Predisposition to Disease skin and connective tissue diseases BRCA2 Protein Biologic marker BRCA1 Protein business.industry Wide local excision Cancer medicine.disease Immunohistochemistry Primary tumor female genital diseases and pregnancy complications Radiation therapy Premenopause Receptors Estrogen Mutation Female Surgery Neoplasm Recurrence Local Tumor Suppressor Protein p53 Receptors Progesterone business |
| Zdroj: | The Breast Journal. 9:167-174 |
| ISSN: | 1524-4741 1075-122X |
| DOI: | 10.1046/j.1524-4741.2003.09307.x |
| Popis: | Conservatively treated premenopausal breast cancer has a higher rate of local relapse as well as an increased genetic predisposition to cancer. The current study's purpose was to evaluate the interactions between BRCA-1/2 status and molecular biologic markers in a cohort of conservatively managed breast cancer patients. Seventy-six premenopausal women treated with breast-conserving surgery and radiation therapy were this study's focus. All patients were treated with wide local excision with or without axillary dissection, followed by radiation to the intact breast. Systemic therapy was administered as clinically indicated. All patients in this study had an available paraffin block from the primary tumor and agreed to undergo complete sequencing of the BRCA-1 and BRCA-2 genes. The primary breast tumor tissue from each patient was immunohistochemically stained for estrogen receptor (ER), progesterone receptor (PR), p53, HER-2/neu, and Proliferating Cell Nuclear Antigen (PCNA). Of the 76 patients tested for BRCA, 50 patients had wild-type BRCA-1 and BRCA-2, 15 had variants of unclear significance, 6 had deleterious mutations in BRCA-1, and 5 had deleterious mutations in BRCA-2. p53 positivity correlated with deleterious mutations in BRCA-1 (p = 0.023), but not in BRCA-2. Though not significant, there was a trend for ER and PR negativity to correlate with BRCA-1 mutation (p = 0.087 and 0.054, respectively); there were no correlations between ER, PR, and BRCA-2. Though not significant, all 11 tumors with BRCA mutations were HER-2/neu negative. Patients with BRCA mutations have a unique molecular profile. These data can be helpful in understanding differences in the biologic behavior of patients with familial breast cancers. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|